By Pam Pollard
When President Donald Trump launched TrumpRx earlier this year, it marked one of the most direct and ambitious efforts in decades to lower prescription drug costs for American families. The program offers steep discounts — in some cases cutting the price of brand-name medications by hundreds of dollars a month — and it does so without creating a new government bureaucracy or expanding federal mandates.
It is a market-driven reform aimed squarely at kitchen-table affordability.
But now, an Oklahoma bill moving through the Legislature risks undercutting that progress before it fully takes hold.
HB 3538, which recently passed out of House Public Health and is expected to be heard by the full Health and Human Services Oversight Committee in the coming weeks, would prohibit pharmacy benefit managers (PBMs) and affiliated entities from holding pharmacy licenses in the state. On its face, the bill is framed as a reform measure. In practice, however, it would likely force hundreds of chain pharmacies to close in Oklahoma.
CVS alone could see as many as 62 of its retail pharmacy locations shuttered along with potentially more than 130 Walmart pharmacy locations, if similar legislation were enacted. Multiply that across other chains that participate in TrumpRx, and the impact becomes significant.
Why does that matter?
Because TrumpRx does not operate in a vacuum. It relies on a broad network of retail pharmacies to dispense discounted medications. Major chains such as CVS Health, Walgreens, Kroger, Albertsons, Walmart and Costco serve as the physical access points where Oklahoma families present their TrumpRx discount cards and receive lower-priced medications.
If those access points disappear, so do the discounts.
This is especially important in a state like Oklahoma, where rural access to health care is already tenuous. Many communities depend on a single pharmacy for everyday prescriptions, specialty medications, and in some cases home delivery. If dozens of locations close, patients will not simply “shift seamlessly” to other providers. They may face longer drives, limited hours, or fewer options altogether.
Independent pharmacies play a valuable role in Oklahoma’s health care ecosystem, and nothing about TrumpRx diminishes that. But even supporters of HB 3538 should acknowledge a simple reality: large chain pharmacies dispense a far greater volume of prescriptions per store than smaller operators. If multiple high-volume stores close, the remaining system will be strained.
That strain lands squarely on patients.
For seniors managing chronic illness, parents filling asthma prescriptions for their children, or veterans relying on specialty medications, convenience is not a luxury — it is part of affordability. A 60-mile round trip to fill a prescription is a hidden tax. Delayed access can mean missed doses. Reduced pharmacy capacity can mean longer wait times and service disruptions.
All of this directly undercuts President Trump’s broader cost-of-living agenda.
TrumpRx was designed as a flagship initiative heading into the 2026 cycle, demonstrating a conservative policy can deliver real savings without expanding government control. The administration has framed it as a historic shift — one that uses private-sector leverage to negotiate lower prices and pass those savings directly to consumers.
But if state-level legislation restricts the very pharmacy networks that make TrumpRx function, Oklahoma risks sending the opposite message: that political fights in the health care sector matter more than delivering affordable medication to families.
There is also a practical consideration. Similar legislation in Arkansas has already faced significant legal challenges and is currently blocked by a federal court. Advancing a comparable measure here could invite costly litigation and prolonged uncertainty for patients and businesses alike.
Oklahoma lawmakers do not need to abandon thoughtful PBM reform to recognize this risk. Transparency and accountability in drug pricing are legitimate goals. But reforms should be carefully calibrated so they do not unintentionally dismantle key components of the president’s affordability strategy.
As HB 3538 heads to full committee, lawmakers should pause and ask a straightforward question: does this legislation make it easier or harder for Oklahomans to access the savings promised under TrumpRx?
If the answer is harder, then the bill deserves reconsideration.
President Trump has made lowering prescription drug prices a signature promise. Oklahoma should not become the state that weakens that effort just as it begins delivering results.
